BioNTech/Pfizer vaccine is less effective against Delta variant
The covid-19 vaccine from BioNTech/Pfizer is not nearly as effective when it comes to the new Delta variant as it is on previous versions of the virus.
This is according to preliminary studies done by the Israeli Ministry of Health, according to the Financial Times.
The studies show that BioNTech/Pfizer's vaccine is 64 percent effective in preventing fully vaccinated people from being infected with the Delta variant. This is lower than for other strains of the virus, where the vaccine is 94 percent effective.
The same studies also show that the vaccine is 93 percent effective in preventing serious illness and hospitalization.
AGC Biologics contacted minister over Danish vaccine collaboration before PM announcement
Sanofi to establish mRNA vaccine center with 400 employees
Pfizer gives Danish PM cold shoulder: rejects idea of starting vaccine production in Denmark
